Prucalopride - Shire-Movetis

Drug Profile

Prucalopride - Shire-Movetis

Alternative Names: R 093877; R 108512; R 93877; Resolor; Resotran; Resotrans; Rezolor; SHP555; SPD-555

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen
  • Developer Janssen; Shire-Movetis NV; University of Calgary
  • Class Amides; Benzofurans; Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Phase II/III Diabetic gastroparesis
  • No development reported Postoperative ileus

Most Recent Events

  • 27 Oct 2017 Shire announces intention to submit NDA to US FDA for Constipation in late fourth quarter of 2017
  • 15 Dec 2016 Biomarkers information updated
  • 15 Dec 2015 Shire plans a phase III trial for Constipation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top